Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Adds Nine Startups to Accelerator Program, Announces £20M Matching Fund

NEW YORK – Illumina announced Monday the funding of nine companies as part of its accelerator programs in the US and the UK.

During the six-month funding cycle, the participants will receive an undisclosed amount of seed investment, access to Illumina sequencing systems and reagents, and lab space adjacent to Illumina's Bay Area and Cambridge, UK campuses, respectively, as well as access to guidance and expertise.

Illumina also announced it has secured £20 million ($27.5 million) in commitments that would match between £500,000 and £4 million in new capital raised by Illumina Accelerator Cambridge graduates within a year. The funding includes £10 million from LifeArc.

The new cohort includes several firms developing diagnostics or genomics tools.

BiotaX Labs, a spinoff of Israel's Technion Research and Development Foundation, is focusing on microbiome-based diagnostics and treatments.

Broken String Biosciences, from Cardiff, UK, is developing a platform of novel sequencing tools to assess genome stability.

MultiplAI Health, a diagnostics company with roots in London and Buenos Aires is leveraging advances in genomics and artificial intelligence to develop universal remote screening for cardiovascular diseases.

Oshun Medical, a diagnostics company from the Bay Area focusing on women's health, is working to predict pregnancy complications.

Illumina Accelerator has invested in more than 45 genomics startups from across the globe, which have collectively raised nearly $600 million in venture capital funding. Last month, Illumina announced it would be partnering with Sequoia Capital China on a genomics incubator in China.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.